17-Dec-2025
Agios Awaits FDA Decision on Mitapivat sNDA for Thalassemia—Key Milestone Remains Pending
Market Chameleon (Mon, 8-Dec 2:35 AM ET)
Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia
Globe Newswire (Mon, 8-Dec 7:00 AM ET)
Market Chameleon (Thu, 20-Nov 5:35 AM ET)
Market Chameleon (Wed, 19-Nov 2:33 AM ET)
Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease
Globe Newswire (Wed, 19-Nov 7:00 AM ET)
Globe Newswire (Mon, 3-Nov 9:01 AM ET)
Agios Reports Third Quarter 2025 Financial Results and Provides Business Update
Globe Newswire (Thu, 30-Oct 6:30 AM ET)
PRNewswire (Sat, 18-Oct 10:00 AM ET)
Business Wire (Fri, 17-Oct 8:15 AM ET)
Agios' PYRUKYND (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia
Globe Newswire (Fri, 17-Oct 8:00 AM ET)
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
Agios Pharmaceuticals trades on the NASDAQ stock market under the symbol AGIO.
As of December 17, 2025, AGIO stock price declined to $25.45 with 1,232,261 million shares trading.
AGIO has a beta of 1.90, meaning it tends to be more sensitive to market movements. AGIO has a correlation of 0.16 to the broad based SPY ETF.
AGIO has a market cap of $1.48 billion. This is considered a Small Cap stock.
Last quarter Agios Pharmaceuticals reported $13 million in Revenue and -$1.78 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.14.
In the last 3 years, AGIO traded as high as $62.58 and as low as $19.80.
The top ETF exchange traded funds that AGIO belongs to (by Net Assets): VTI, VB, IWM, XBI, VBK.
AGIO has underperformed the market in the last year with a price return of -40.4% while the SPY ETF gained +11.8%. AGIO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -30.7% and -5.7%, respectively, while the SPY returned +2.0% and -1.5%, respectively.
AGIO support price is $25.12 and resistance is $27.06 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AGIO shares will trade within this expected range on the day.
